EMcision Ltd., a privately-held company headquartered in London, UK that develops and commercializes proprietary medical devices, today announced that it and its subsidiaries have been acquired by Boston Scientific, the world’s premier endoscopic devices company.
Founded by internationally renowned surgeon and inventor, Prof. Nagy Habib, EMcision develops innovative devices including the HabibTM 4X, the HabibTM EndoHPB and the HabibTM EUS RFA. Those products have benefited close to 100,000 patients suffering from cancers of the liver, pancreas and bile ducts.
EMcision’s flagship product, the HabibTM EndoHPB, was the world’s first endoscopic device for tumour ablation via ERCP using radiofrequency energy in patients with advanced and inoperable pancreatic cancer and cholangiocarcinoma.
“Recently, two randomised clinical trials showed independently a statistically significant survival advantage for patients treated with the HabibTM EndoHPB,” said Prof. Nagy Habib, EMcision’s Chairman and founder. “This new treatment has empowered endoscopists with a very useful device for management of these unfortunate patients with advanced cancer.”
EMcision devices are sold in 38 countries around the world and used by surgeons and endoscopists in most of the top US cancer centres such as MD Anderson, Memorial Sloan Kettering, Mayo Clinic, Cleveland Clinic, Johns Hopkins, Massachusetts General and Stanford.
“By partnering with Boston Scientific, we will continue delivering on our mission of improving the quality of life of cancer patients on a much larger scale. Boston Scientific has the resources and the know-how to further improve our technology, expand clinical indications and make it available to many more patients,” said Cherif Habib, EMcision’s outgoing CEO.
Boston Scientific, headquartered in Marlborough, Massachusetts, was founded in 1979 and employs over 27,000 people. Their products, across six business divisions, treat over 24 million patients every year.
Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.
Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.
Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.